2022 年第三季度报告 证券代码：600222 证券简称：太龙药业 河南太龙药业股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人尹辉、主管会计工作负责人赵海林及会计机构负责人（会计主管人员）胡志权保 证季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 单位：元 币种：人民币 | 项目 | 本报告期金额 | 年初至报告期末 | 说明 | | --- | --- | --- | --- | | | | 金额 | | | 非流动性资产处置损益 | 109,129.93 | 30,343.03 | | | 越权审批，或无正式批准文件，或偶发性的税收返还、 | | | | | 减免 | | | | | 计入当期损益的政府补助，但与公司正常经营业务密切 | | | | | 相 ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 863,676,913.87, representing a year-on-year increase of 14.87%[18]. - The net profit attributable to shareholders decreased by 193.56% to a loss of CNY 25,432,310.28, primarily due to a decline in revenue from the pharmaceutical formulation business and legal compensation from a subsidiary[20]. - The net cash flow from operating activities decreased by CNY 66,380,836.05, reflecting a slowdown in sales collections due to the impact of the pandemic[20]. - The revenue from traditional Chinese medicine segment increased by 33.34% due to higher sales volume and price adjustments[19]. - The revenue from pharmaceutical research services grew by 25.34% driven by business expansion and capacity enhancement[19]. - The revenue from pharmaceutical formulation business declined by 23.41% due to restrictions on core product sales from pandemic control policies[19]. - The basic earnings per share for the first half of 2022 was -CNY 0.0452, a decrease of 193.20% compared to the same period last year[19]. - The weighted average return on net assets decreased by 3.23 percentage points to -1.51%[19]. - The company reported a non-recurring loss of approximately ¥10.1 million, primarily due to non-operating expenses and losses from financial instruments[23]. - The company achieved operating revenue of 863.68 million yuan, a year-on-year increase of 14.87%[41]. - The net profit attributable to shareholders was -25.43 million yuan, a decrease of 52.5 million yuan compared to the same period last year, primarily due to a decline in revenue from the pharmaceutical formulation business and litigation compensation payments[41]. Assets and Liabilities - The company's total assets decreased by 6.63% to CNY 3,532,867,336.33 compared to the end of the previous year[18]. - The net assets attributable to shareholders increased slightly by 0.03% to CNY 1,660,987,096.22[18]. - The company's cash and cash equivalents decreased by 57.48% to CNY 161,812,932.03 from CNY 380,549,308.28, attributed to slower sales collections and reduced bank financing[55]. - Long-term equity investments increased significantly by 315.24% to CNY 65,295,383.43, compared to CNY 15,724,611.04, indicating new investments in associated companies[55]. - The company's total liabilities decreased from ¥2,006,135,829.69 to ¥1,724,127,783.32, a decrease of approximately 14.0%[129]. - The company's total assets decreased from ¥3,783,772,407.22 to ¥3,532,867,336.33, representing a decline of about 6.6%[129]. Research and Development - The company has a research and development team of nearly 1,000 people, led by top domestic and international experts, and has advanced research and testing equipment, positioning it as a leader in R&D capabilities in the industry[40]. - The company processed over 4,200 tons of traditional Chinese medicine pieces and brewed 840,000 doses, further enhancing production and sales scale[42]. - The company participated in the research and development of nearly 123 projects, with 30 drug registration applications under review, including 2 innovative drugs and 18 improved new drugs[43]. - The company established a new R&D platform in Chongqing and Zhengzhou, enhancing its drug development service capabilities[45]. - The R&D team consists of 945 members, with 238 holding master's or doctoral degrees, accounting for 25.19%[45]. - Research and development expenses rose significantly by 57.40% to CNY 44,939,144.73, compared to CNY 28,550,211.51, as the company increased investment in product development[48]. Market and Business Strategy - The main business segments include pharmaceutical manufacturing, traditional Chinese medicine, and drug research and development services, with a focus on oral preparations and traditional Chinese medicine pieces[25]. - The pharmaceutical manufacturing segment features exclusive products such as the concentrated version of Shuanghuanglian oral liquid and pediatric formulations, contributing significantly to revenue[25]. - The drug research and development services are provided by a subsidiary, focusing on preclinical studies, clinical CRO research, and regulatory submissions, aimed at reducing R&D risks and timelines for clients[26]. - The company aims to expand its market presence by deepening relationships with existing clients and exploring new customer segments through professional marketing strategies[29]. - The company has leveraged its regional advantages to procure and sell traditional Chinese medicine and pharmaceuticals, enhancing its market position[31]. - The company has established a comprehensive supply chain for traditional Chinese medicine, ensuring quality and cost control through long-term partnerships with local farmers[28]. Environmental and Social Responsibility - The company has not experienced any environmental pollution incidents or received administrative penalties from environmental protection authorities during the reporting period[79]. - The company reported a chemical oxygen demand (COD) discharge concentration of 18-72 mg/l, with a total discharge of 0.445 tons in the first half of 2022, well below the permitted limit of 100 mg/l[80]. - The company has implemented an emergency response plan for environmental incidents, registered with the local environmental authority[85]. - The company promotes clean production and has established a standardized system for production and management, aiming to reduce waste generation and improve resource efficiency[93]. - The company has engaged in land circulation in medicinal material production areas, helping local farmers increase income and contributing to rural revitalization[94]. - The company utilizes natural gas as a clean energy source to reduce emissions of waste gas pollutants[92]. Corporate Governance and Shareholder Relations - The company held its first extraordinary general meeting on February 25, 2022, where five proposals were approved, including the reappointment of the accounting firm[67]. - The company reported no dividend distribution or capital reserve transfer plan for the first half of 2022, with no shares or cash dividends proposed[72]. - The company has implemented the second phase of its employee stock ownership plan in 2021, transferring 11,083,700 shares at a price of 4.49 CNY per share, with a lock-up period of 12 months[75]. - The company approved a share repurchase plan with a budget between 40 million RMB and 80 million RMB, with a maximum repurchase price of 7 RMB per share[116]. - The total number of ordinary shareholders as of the end of the reporting period was 41,394[118]. - The largest shareholder, Zhengzhou Tai Rong Industrial Investment Co., Ltd., held 82,441,168 shares, accounting for 14.37% of total shares[120]. Financial Reporting and Compliance - The financial statements are prepared in accordance with the enterprise accounting standards[165]. - The accounting period for the company runs from January 1 to December 31 each year[166]. - The company's accounting currency is Renminbi (CNY)[168]. - The company recognizes financial assets or liabilities when it becomes a party to a financial instrument contract[191]. - Financial assets are classified at initial recognition based on the company's business model and cash flow characteristics, including amortized cost, fair value through other comprehensive income, and fair value through profit or loss[192]. - The company assesses significant increases in credit risk by comparing the risk of default at the reporting date with the risk at initial recognition, considering adverse changes in business, financial, or economic conditions[199].

证券代码：600222 证券简称：太龙药业 编号：临 2022-036 河南太龙药业股份有限公司 关于参加河南辖区上市公司 2022 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强投资者的互动交流，河南太龙药业股份有限公司定 于 2022 年 5 月 30 日（周一）15:30-17:00 参加在全景网举办的"真 诚沟通 传递价值"河南辖区上市公司 2022 年投资者网上集体接待日 活动，本次活动将采用网络远程的方式举行，投资者可登录"全景·路 演天下"（http://rs.p5w.net）参与本次互动交流。 出席本次网上集体接待日活动的人员有：公司董事长尹辉先生、 总经理罗剑超先生、董事会秘书冯海燕女士、财务负责人赵海林先生 （如有特殊情况，参会人员将可能进行调整），欢迎广大投资者积极 参与。 特此公告。 河南太龙药业股份有限公司董事会 2022 年 5 月 26 日 ...

Financial Performance - The company's operating revenue for Q1 2022 was CNY 422,282,414.89, representing a year-on-year increase of 1.52%[5] - The net profit attributable to shareholders of the listed company was CNY 2,329,695.73, showing a significant decrease of 91.33% compared to the same period last year[5] - The basic earnings per share (EPS) was CNY 0.0041, down 91.48% year-on-year[6] - Total revenue for Q1 2022 was CNY 422,282,414.89, a slight increase of 0.78% compared to CNY 415,958,437.10 in Q1 2021[22] - Net profit for Q1 2022 was CNY 2,166,570.19, a significant decrease of 91.86% from CNY 26,632,438.79 in Q1 2021[23] - The company's operating profit for Q1 2022 was CNY 2,976,218.24, down from CNY 30,641,135.93 in Q1 2021, indicating a decline of 90.31%[23] - Basic and diluted earnings per share for Q1 2022 were CNY 0.0041, down from CNY 0.0481 in Q1 2021, a decline of 91.49%[24] - Other comprehensive income for Q1 2022 was negative CNY 4,641,036.70, contrasting with a positive CNY 196,461,366.30 in Q1 2021[24] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,789,529,131.70, a slight increase of 0.15% from the end of the previous year[6] - The total assets as of Q1 2022 amounted to CNY 3,789,529,131.70, slightly up from CNY 3,783,772,407.22 at the end of Q1 2021[21] - Total liabilities for Q1 2022 were CNY 1,884,367,020.68, down from CNY 2,006,135,829.69 in Q1 2021, a decrease of 6.09%[21] - The company's total equity increased to CNY 1,905,162,111.02 in Q1 2022, compared to CNY 1,777,636,577.53 in Q1 2021, marking an increase of 7.16%[21] Cash Flow - The net cash flow from operating activities was negative at CNY -151,971,688.24, indicating a significant cash outflow[5] - Cash inflow from operating activities for Q1 2022 was $363.89 million, up from $312.19 million in Q1 2021, representing a 16.5% increase[26] - Net cash outflow from operating activities for Q1 2022 was -$151.97 million, compared to -$43.52 million in Q1 2021, indicating a significant decline[27] - Cash inflow from investment activities for Q1 2022 was $591.64 million, a substantial increase from $162.82 million in Q1 2021, marking a 263.5% rise[27] - Cash inflow from financing activities for Q1 2022 was $102.20 million, down from $165.15 million in Q1 2021, showing a decrease of 38.1%[27] - The ending cash and cash equivalents balance for Q1 2022 was $214.11 million, down from $493.69 million in Q1 2021, indicating a decline of 56.7%[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 50,264[10] - The company’s major shareholder changed to Zhengzhou Tai Rong Industrial Investment Co., Ltd., which acquired 82,441,168 shares, accounting for 14.37% of the total share capital[13] - The company’s board of directors and supervisory board were restructured on February 25, 2022, with a new chairman elected[13] - The company’s repurchase account held 10,846,107 shares, representing 1.89% of the total shares as of the reporting period[12] Expenses and Investments - The decline in net profit was primarily due to the sales restrictions on four categories of drugs, leading to decreased revenue and gross profit[8] - The company faced increased sales expenses as it intensified market promotion for other product lines[8] - Research and development expenses increased to CNY 19,581,712.93 in Q1 2022, compared to CNY 14,409,179.35 in Q1 2021, reflecting a growth of 36.06%[23] - Non-recurring gains and losses amounted to a net loss of CNY -120,616.38 after tax adjustments[8] - The company received financial support of up to 1.2 billion RMB from its indirect controlling shareholder, with the first tranche of 419 million RMB already received[15] - The company’s long-term equity investments stood at 15,473,270.37 RMB as of March 31, 2022, slightly down from 15,724,611.04 RMB at the end of 2021[17] - The company’s total liabilities and equity structure will be impacted by the recent changes in major shareholders and financial support arrangements[13][15]

Financial Performance - In 2021, the company achieved a net profit attributable to shareholders of RMB 5,995,375.55, a decrease of 79.50% compared to RMB 29,240,862.39 in 2020[5]. - The company's operating revenue for 2021 was RMB 1,604,516,940.00, representing a year-on-year increase of 13.23% from RMB 1,417,097,311.59 in 2020[21]. - The net cash flow from operating activities increased by 35.72% to RMB 99,655,159.11 in 2021, compared to RMB 73,427,546.30 in 2020[21]. - The total assets of the company as of the end of 2021 were RMB 3,783,772,407.22, an increase of 11.64% from RMB 3,389,394,715.08 at the end of 2020[21]. - The net profit after deducting non-recurring gains and losses was RMB 36,179,012.56, a significant increase of 159.11% compared to RMB 13,962,693.07 in 2020[21]. - Basic earnings per share (EPS) fell by 80.00% to RMB 0.0107, while diluted EPS remained the same[22]. - The weighted average return on equity (ROE) decreased by 1.73 percentage points to 0.37%[22]. - The company reported a significant loss of RMB 30.18 million from non-recurring gains and losses, impacting overall profitability[27]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 0.10 per share, totaling RMB 5,630,401.76, which accounts for 93.91% of the net profit attributable to shareholders for 2021[5]. - For the 2021 fiscal year, the company plans to distribute a cash dividend of CNY 0.10 per share (including tax), amounting to CNY 5,630,401.76, which represents 93.91% of the net profit attributable to shareholders of the parent company[172]. Business Growth and Strategy - The company's operating revenue increased by 13.23% year-on-year, driven by a 35.74% growth in pharmaceutical R&D services and a 19.31% increase in traditional Chinese medicine products[23]. - The company is focusing on expanding its market presence and enhancing brand promotion for its traditional Chinese medicine products[23]. - The company is actively expanding its market presence by integrating existing traditional Chinese medicine products and increasing marketing investments in targeted product combinations[34]. - The company aims to enhance product quality through strict adherence to production standards and quality management practices[49]. - The company is committed to expanding its market presence and enhancing brand influence through strategic partnerships and marketing initiatives[56]. Research and Development - The company has 906 personnel in the R&D team, with 23.62% holding master's or doctoral degrees, indicating a strong talent pool[36]. - The company has established multiple platforms for drug research, focusing on high-end formulations and innovative drug research, including preclinical and clinical trial services[57]. - The company has initiated 56 new research projects in high-end generic and innovative drugs, bringing the total number of ongoing projects to 267[103]. - The company is focusing on high-barrier therapeutic areas such as cardiovascular, anti-tumor, and digestive system drugs, aligning R&D efforts with market demand[103]. - The company is conducting clinical research on TLZ0005, a new drug for breast disease, which is currently in the clinical research phase[104]. Environmental Responsibility - The company was listed as a key pollutant discharge unit in Zhengzhou for 2021, with strict adherence to national standards for pollutant treatment and discharge[184]. - No environmental pollution incidents occurred during the reporting period, and the company did not face any administrative penalties from environmental protection authorities[185]. - The company has implemented a comprehensive environmental monitoring plan, with third-party testing confirming that all pollutants are within regulatory limits[192]. - The company emphasizes a low-carbon production philosophy, advocating for resource conservation and green practices among employees[197]. Governance and Management - The governance structure of the company is robust, ensuring compliance with laws and regulations while protecting shareholder interests[134]. - The company maintains transparent communication with investors, ensuring their rights are protected and fostering good investor relations[136]. - The company completed the election of the ninth board of directors and the ninth supervisory board on February 25, 2022, with new appointments including Yin Hui as chairman and Luo Jianchao as general manager[143]. - The company has proposed to allocate profits for the year 2020, indicating a focus on shareholder returns[139]. - The company has established a comprehensive human resources management system, including salary and welfare, performance evaluation, training management, and promotion systems[169]. Market Trends and Industry Insights - The Chinese CRO market is expected to grow at a compound annual growth rate (CAGR) of 20.22% from 2020 to 2030, reaching a market size of approximately 329.2 billion yuan by 2030[42]. - The global CRO market is projected to reach $168.9 billion by 2030, with a CAGR of 9.95% from 2020 to 2030[42]. - The pharmaceutical manufacturing industry achieved operating revenue of 2,928.85 billion yuan in 2021, growing by 20.1% year-on-year, indicating a robust industry trend[40]. - The ongoing reforms in the medical insurance system are expected to further support the development of TCM services and products[47]. Community Engagement - The company donated over 1.5 million yuan worth of medicines to support disaster relief efforts following severe flooding[198]. - The company aims to support rural economic development by promoting standardized planting techniques and processing projects for traditional Chinese medicine[199].

Financial Performance - The company's operating revenue for Q3 2021 was ¥366,001,686.59, representing a 15.26% increase compared to ¥317,472,513.26 in the same period last year[4] - The net profit attributable to shareholders was ¥1,117,516.22, a significant decrease of 170.59% from ¥1,321,298.24 in the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥2,970,618.20, showing a 164.17% increase from a loss of ¥3,964,416.62 in the same period last year[4] - Total revenue for the first three quarters of 2021 reached ¥1,117,873,585.28, an increase of 15.8% compared to ¥965,315,174.14 in the same period of 2020[23] - Net profit for the third quarter of 2021 was ¥29,135,082.76, compared to ¥23,451,461.66 in the same quarter of 2020, representing a growth of 24.0%[24] - The company reported a total comprehensive income of ¥152,478,384.04 for the third quarter of 2021, compared to ¥209,585,308.49 in the same quarter of 2020, a decrease of 27.2%[25] Cash Flow and Liquidity - The net cash flow from operating activities increased by 227.22%, reaching ¥63,005,957.11 compared to ¥21,383,911.63 in the previous year[4] - Cash inflow from operating activities for the first three quarters of 2021 was CNY 1,192,818,670.20, an increase of 19.5% compared to CNY 998,252,098.80 in the same period of 2020[27] - Net cash flow from operating activities in Q3 2021 was CNY 63,005,957.11, significantly up from CNY 19,255,063.59 in Q3 2020, representing a growth of 227.5%[28] - The ending cash and cash equivalents balance for Q3 2021 was CNY 536,222,847.19, compared to CNY 463,493,644.76 at the end of Q3 2020, reflecting a year-over-year increase of 15.7%[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,857,651,202.83, reflecting a 13.82% increase from ¥3,389,394,715.08 at the end of the previous year[5] - Total liabilities as of Q3 2021 amounted to ¥2,133,844,838.86, compared to ¥1,858,823,901.11 in Q3 2020, indicating an increase of 14.8%[20] - The company's total assets increased to ¥3,857,651,202.83 in Q3 2021, up from ¥3,389,394,715.08 in Q3 2020, marking a growth of 13.8%[20] - The total liabilities amounted to approximately $1.86 billion, with a slight increase of $44.47 million compared to the previous period[32] Shareholder Equity - The equity attributable to shareholders increased by 11.57%, amounting to ¥1,621,639,527.76 compared to ¥1,453,415,199.81 at the end of the previous year[5] - The company's equity attributable to shareholders reached ¥1,621,639,527.76 in Q3 2021, up from ¥1,453,415,199.81 in Q3 2020, reflecting an increase of 11.6%[20] - Total equity reached approximately $1.53 billion, with the equity attributable to shareholders amounting to approximately $1.45 billion[32] Investments and Acquisitions - The company completed the acquisition of a 33.95% stake in Ta Long Health Industry Investment Co., Ltd., increasing its ownership to 80.40%, which allows for control over the company[5] - The company invested RMB 2,090,000 to acquire 95% of Zhengzhou Pairui Pharmaceutical Co., Ltd. to develop small molecule CDMO business[14] - The company established a wholly-owned subsidiary, Zhengzhou Weixian Pharmaceutical Technology Co., Ltd., with an investment of RMB 3,000,000 to enhance its drug research and registration capabilities[14] Inventory and Assets Management - The total inventory increased to RMB 404,567,769.44 from RMB 348,143,680.47, reflecting a rise of approximately 16.1%[18] - Long-term equity investments rose to RMB 40,678,587.06 from RMB 19,633,703.01, marking an increase of about 106.5%[18] - The company’s goodwill remained stable at RMB 286,492,789.75, unchanged from the previous period[18] Financial Standards and Compliance - The company adopted new leasing standards starting in 2021, which adjusted the financial statements accordingly, impacting the balance sheet figures[29] - The company adopted the new leasing standards effective January 1, 2021, which is not expected to significantly impact net profit, total assets, or net assets[33]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 751.87 million, representing a 16.07% increase compared to CNY 647.76 million in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2021 was CNY 27.18 million, a slight increase of 1.62% from CNY 26.75 million in the previous year[18]. - The basic earnings per share for the first half of 2021 were CNY 0.0485, a decrease of 1.02% from CNY 0.0490 in the same period last year[20]. - The weighted average return on net assets for the first half of 2021 was 1.72%, down by 0.21 percentage points from 1.93% in the previous year[20]. - Revenue increased by 16.07% year-on-year, driven by the gradual release of capacity in drug research and development services, with drug formulation services revenue decreasing by 12.14%[21]. - Drug research and development services revenue grew by 65.61%, while traditional Chinese medicine (TCM) revenue increased by 30.62%[21]. - The revenue from the pharmaceutical formulation business was 241.40 million yuan, a year-on-year decrease of 12.14% due to the decline in demand for pandemic-related products[42]. - The revenue from the Chinese herbal pieces business reached 333.01 million yuan, a year-on-year increase of 30.62%[43]. - The pharmaceutical research and development service segment reported revenue of 135.68 million yuan, with a significant year-on-year growth[44]. Cash Flow and Investments - The net cash flow from operating activities decreased significantly by 58.76% to CNY 7.37 million, down from CNY 17.88 million in the same period last year[18]. - The company’s investment activities generated a net cash flow of 330.53 million yuan, a 162.25% increase compared to the previous year[47]. - The company’s cash flow from operating activities decreased by 58.76% to 73.74 million yuan, attributed to increased project expenditures[47]. - The company’s cash flow from financing activities resulted in a net outflow of RMB 172,346,391.25, contrasting with a net inflow of RMB 38,409,602.54 in the same period last year[132]. - The total cash and cash equivalents at the end of the first half of 2021 were RMB 355,396,594.61, a decrease from RMB 396,357,422.29 at the end of the first half of 2020[132]. Assets and Liabilities - The total assets of the company at the end of the reporting period were CNY 3.66 billion, reflecting a 7.86% increase from CNY 3.39 billion at the end of the previous year[19]. - The total liabilities as of June 30, 2021, were CNY 1,200,000,000.00, compared to CNY 1,100,000,000.00 at the end of 2020, indicating an increase of about 9.09%[117]. - The company reported a total equity of CNY 1,200,000,000.00, unchanged from the previous period, maintaining a stable equity position[117]. - The total liabilities decreased to ¥1,055,888,867.17 from ¥1,211,910,813.37, a reduction of 12.88%[124]. - The total equity increased to ¥1,433,302,283.83, up 3.00% from ¥1,389,796,721.54 in the previous year[124]. Research and Development - The company’s R&D expenses increased by 8.60% to 28.55 million yuan, reflecting ongoing investment in innovation[47]. - Research and development expenses for the first half of 2021 were ¥28,550,211.51, slightly higher than ¥26,289,026.05 in the same period of 2020[126]. - The company is focusing on expanding its TCM production and sales, enhancing upstream TCM material planting bases, and improving quality traceability systems[25]. - The drug research and development services segment aims to provide comprehensive technical services to pharmaceutical companies, helping to reduce R&D risks and shorten development cycles[25]. Governance and Compliance - The company did not report any non-operating fund occupation by controlling shareholders or related parties during the reporting period[5]. - There were no significant changes in the company's governance structure or major financial indicators during the reporting period[15]. - The company has established measures to prevent conflicts of interest and protect shareholder rights in related transactions[96]. - The company has committed to strictly adhering to the decision-making procedures for related party transactions and timely information disclosure obligations[100]. Environmental Responsibility - The company has not experienced any environmental pollution incidents or received administrative penalties during the reporting period[76]. - The wastewater treatment facility at the company processes 1,000 tons of wastewater daily, utilizing a series of advanced treatment processes to ensure compliance with discharge standards[79]. - The company has implemented measures to reduce carbon emissions, aligning with national goals to peak carbon emissions by 2030 and achieve carbon neutrality by 2060[89]. - The company adheres to strict environmental management practices, emphasizing sustainable development and ecological responsibility[88]. Market Position and Recognition - The company has been recognized as one of the top 100 pharmaceutical companies in China and has maintained a strong market position in the traditional Chinese medicine sector[35]. - The company has established a nationwide marketing network for drug formulation sales, leveraging partnerships with distributors and retail chains to enhance brand influence[27]. - The company has a strong brand presence, with its trademark recognized as a famous Chinese trademark and its products receiving high recommendation rates from pharmacy staff[36]. Risks and Challenges - The company has outlined potential risks in its management discussion and analysis section, urging investors to pay attention to these risks[5]. - The company faces risks related to raw material prices and supply, influenced by various factors such as planting area and climate, which can significantly impact operational costs[62]. - Accounts receivable have increased due to business expansion, raising operational costs and potential bad debt risks, prompting the company to enhance internal controls and cash flow management[63].

证券代码：600222 证券简称：太龙药业 编号：临 2021-029 河南太龙药业股份有限公司 关于参加河南辖区上市公司 2021 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强投资者的互动交流，河南太龙药业股份有限公司定 于 2021 年 6 月 8 号（周二）16:00-17:20 参加在全景网举办的"真 诚沟通 传递价值"河南辖区上市公司 2021 年投资者网上集体接待日 活动，本次活动将采用网络远程的方式举行，投资者可登录"全景·路 演天下"（http://rs.p5w.net）参与本次互动交流。 出席本次网上集体接待日活动的人员有：公司董事兼总经理罗剑 超先生、董事会秘书冯海燕女士（如有特殊情况，参会人员将可能进 行调整），欢迎广大投资者积极参与。 特此公告。 河南太龙药业股份有限公司董事会 2021 年 6 月 4 日 ...

Financial Performance - Net profit attributable to shareholders decreased by 24.92% to CNY 26,863,537.79 compared to the same period last year[5] - Operating income rose by 2.33% to CNY 415,958,437.10, indicating stable business growth after excluding pandemic-related fluctuations[5] - Basic and diluted earnings per share decreased by 29.78% to CNY 0.0481[5] - The weighted average return on equity decreased by 1.01 percentage points to 1.81%[5] - The company reported a net profit increase, with retained earnings growing to CNY 211,117,015.25 from CNY 184,253,477.46, a rise of approximately 14.6%[23] - Net profit for Q1 2021 was ¥26,632,438.79, down 23.5% from ¥34,810,144.04 in Q1 2020[31] - The company reported a gross profit margin of approximately 9.1% in Q1 2021, compared to 10.0% in Q1 2020[30] Assets and Liabilities - Total assets increased by 10.32% year-on-year to CNY 3,739,251,867.46[5] - Non-current assets totaled CNY 1,802,034,941.35, compared to CNY 1,507,019,827.12, indicating a rise of about 19.6%[22] - Total current assets reached ¥1,937,216,926.11, an increase from ¥1,882,374,887.96 in the previous period[21] - Total liabilities amounted to CNY 1,935,821,435.40, an increase from CNY 1,858,823,901.11, reflecting a growth of about 4.1%[23] - Current liabilities decreased slightly to CNY 1,483,177,309.65 from CNY 1,503,881,432.98, a reduction of approximately 1.6%[22] - Shareholders' equity rose to CNY 1,803,430,432.06, up from CNY 1,530,570,813.97, marking an increase of approximately 17.8%[23] Cash Flow - Cash flow from operating activities showed a significant decline of 383.02%, resulting in a net cash outflow of CNY -43,519,728.40[5] - The company reported a net cash flow from operating activities of -¥43,519,728.40, a decrease of 383.02% compared to the previous year[15] - The net cash flow from operating activities was -¥141,881,125.61, compared to -¥40,652,629.81 in the same quarter last year, indicating a significant decline[40] - The total cash outflow from operating activities was ¥239,829,370.85, compared to ¥284,536,051.96 in the previous year, showing a reduction in cash outflow[40] - The company experienced a net increase in cash and cash equivalents of -¥86,561,400.01, compared to an increase of ¥55,603,907.64 in the same quarter last year[41] Investments and Shareholder Information - The largest shareholder, Zhengzhou Zhongsheng Industrial Group Co., Ltd., holds 23.08% of the shares, with 132,441,168 shares pledged[9] - The company completed the acquisition of a 3.33% stake in the Heze Jingang Advanced Manufacturing Equity Investment Fund for ¥10 million[16] - Other equity investments increased to ¥781,642,554.19, accounting for 20.90% of total assets, up 53.36% from the previous period[11] - The total number of shareholders reached 45,174, indicating a stable shareholder base[9] Comprehensive Income - The total comprehensive income for Q1 2021 was ¥223,093,805.09, significantly higher than ¥34,810,144.04 in Q1 2020[31] - The company reported a significant increase in other comprehensive income, totaling ¥196,461,366.30 in Q1 2021[31] - The company’s other comprehensive income increased by 102.11% to ¥312,651,724.39, mainly due to fair value increases of financial assets held by subsidiaries[11] Operational Costs - Total operating costs for Q1 2021 were ¥378,040,728.36, up 4.9% from ¥360,308,646.98 in Q1 2020[30] - Research and development expenses for Q1 2021 were ¥14,409,179.35, slightly decreased from ¥14,700,980.86 in Q1 2020[30] - The company incurred financial expenses of ¥19,836,422.82 in Q1 2021, an increase from ¥18,890,738.43 in Q1 2020[30] Market Position and Strategy - The company plans to continue focusing on stable growth and product development despite recent financial challenges[5] - The company has not reported any new product launches or significant market expansions in this quarter[44]

Financial Performance - In 2020, the company achieved a net profit attributable to shareholders of 29,240,862.39 CNY, a decrease of 34.16% compared to the previous year[5]. - The total operating revenue for 2020 was 1,417,097,311.59 CNY, representing an increase of 8.03% from 2019[25]. - The company reported a significant decline in net profit compared to 2019, which was 44,414,622.07 CNY[25]. - The company's net profit attributable to shareholders decreased by 34.16% year-on-year, primarily due to increased raw material costs and fixed expenses during the pandemic[28]. - Basic earnings per share decreased by 33.04% to RMB 0.0535, reflecting the overall decline in profitability[27]. - The weighted average return on equity fell to 2.10%, a decrease of 1.08 percentage points compared to the previous year[27]. - The company reported a total revenue of 15,278,169.32, with a year-on-year increase of 5,772,488.18[35]. - The company achieved operating revenue of 1,417.10 million yuan in 2020, representing a year-on-year growth of 8.03%[62]. - The net profit attributable to shareholders was 29,240,900 CNY, with a net profit of 13,962,700 CNY after deducting non-recurring gains and losses[62]. Cash Flow and Dividends - The cash dividend proposed is 0.16 CNY per share, totaling 9,008,642.82 CNY, which accounts for 30.81% of the net profit attributable to shareholders[5]. - As of December 31, 2020, the profit available for distribution to shareholders was 184,253,477.46 CNY[5]. - Operating cash flow increased by 76.82% year-on-year, attributed to a higher proportion of cash collections during the reporting period[29]. - The company reported a significant increase in net cash flow from operating activities, amounting to 73,427,546.30 CNY, a 76.82% increase compared to the previous year[64]. - Net cash inflow from financing activities was 209.57 million yuan, a significant increase of 211.48% year-on-year, driven by increased bank financing and capital contributions[83]. Investments and Acquisitions - The company acquired a 33.95% stake in Tailong Health, increasing its ownership to 80.40%, allowing for control over the entity[27]. - The company increased its investment in the healthcare sector, acquiring control of Tailong Health Industry Investment Co., Ltd., and established two funds with a fair value increase of 24.6 million CNY during the reporting period[60]. - The company completed a capital increase of RMB 130 million from Jinggang Fund, acquiring a 20% stake in Shenlanhai[157]. - The company acquired 33.95% equity of Tailong Health from its controlling shareholder for RMB 127.9 million during the reporting period[157]. Revenue by Segment - Revenue from traditional Chinese medicine oral liquid products increased by 35.88% year-on-year, driven by market demand during the pandemic[28]. - The pharmaceutical formulation business generated revenue of 478.93 million yuan, with a year-on-year increase of 32.76%[56]. - The revenue from the clinical CRO services segment was 238.79 million yuan, reflecting a year-on-year growth of 6.45%[59]. - Revenue from traditional Chinese medicine pieces decreased by 4.00% year-on-year, with a gross margin decline of 18.69 percentage points[70]. - Pharmaceutical distribution revenue fell by 31.29% year-on-year, primarily due to the company's strategic adjustment to reduce drug distribution operations[70]. - Revenue from herbal medicine trading increased by 31.50% year-on-year, driven by growth in orders for high-quality ecological medicinal materials[70]. Research and Development - The company aims to enhance its drug research and development services, focusing on reducing risks and shortening development cycles for clients[37]. - The company’s R&D services cover the entire pharmaceutical development chain, including preclinical research and clinical CRO services, aimed at maximizing client returns by reducing time and cost[41]. - R&D expenses rose by 7.21% to 63,664,588.06 CNY, reflecting the company's commitment to innovation[64]. - The company has over 80 ongoing R&D projects, primarily in cardiovascular, anti-tumor, and digestive system areas, including clinical trials for new drugs[107]. - R&D investment for the reporting period accounted for 4.50% of total revenue, with a year-on-year increase of 7.13% in R&D spending[112]. Corporate Governance and Compliance - The company has committed to reducing and regulating related party transactions with its controlling shareholders to avoid conflicts of interest[144]. - The controlling shareholder promised not to engage in any competitive business activities within China that could harm the company's interests[144]. - The company is focused on ensuring compliance with legal and regulatory requirements in all related party transactions[144]. - The company aims to maintain transparency and fairness in its dealings with related parties to protect shareholder interests[144]. - The company has implemented the new revenue recognition standards since January 1, 2020, which did not have a significant impact on its financial position and operating results[147]. Environmental Responsibility - The company reported that the concentrations and total emissions of SO2 and nitrogen oxides from both production sites were below the approved discharge limits[179]. - The company has not experienced any environmental pollution incidents or received administrative penalties during the reporting period[173]. - The wastewater treatment facility has a daily processing capacity of 1,000 tons, and the treatment process includes multiple stages to ensure compliance with discharge standards[177]. - The company has implemented a self-monitoring scheme for environmental compliance, with third-party monitoring showing all pollutants meet discharge standards[182]. Shareholder Information - The total number of ordinary shares after the recent changes is 573,886,283, with 99.39% being freely tradable[187]. - The company completed a non-public issuance of A-shares totaling 77,277,371 shares, increasing the total share capital from 496,608,912 shares to 573,886,283 shares[188]. - The total number of ordinary shareholders increased from 45,174 to 50,196, representing a growth of approximately 11.3%[191]. - The largest shareholder, Zhengzhou Zhongsheng Industrial Group Co., Ltd., holds 132,441,168 shares, accounting for 23.08% of the total shares[194]. Social Responsibility - The company donated 6 million RMB worth of medicines to medical and public welfare institutions in response to the COVID-19 pandemic[171]. - The company has established long-term stable Chinese medicinal material supply bases to support local farmers, contributing to poverty alleviation efforts[167]. - The company reported a total of 37.14 million RMB invested in poverty alleviation initiatives during the reporting period[168].